2023 World Conference on Lung Cancer (Posters)-EP07.05. Application of Neoadjuvant Chemoimmunotherapy in A Specific Group of Stage IB NSCLC

EP07.05. Application of Neoadjuvant Chemoimmunotherapy in A Specific Group of Stage IB NSCLC - PDF(Abstract)

Pdf Summary

This study investigated the feasibility of using neoadjuvant chemoimmunotherapy followed by modified surgery in a specific group of stage IB non-small cell lung cancer (NSCLC) patients. This specific subset of patients had tumors that were close to the lobar bronchi orifice or invading pulmonary artery branches, requiring more extensive surgeries such as bilobectomy, sleeve lobectomy, or pneumonectomy. The aim of the study was to find an alternative treatment paradigm that would decrease trauma and lung tissue loss.<br /><br />The study enrolled 10 male patients with central-type squamous cell carcinoma who were heavy smokers. These patients received 2-4 cycles of neoadjuvant chemoimmunotherapy before undergoing surgery. The median tumor size decreased from 3.2 cm to 0.5 cm after neoadjuvant therapy. The objective response rate was 90%, with complete regression observed in 80% of patients. Pathological down-staging was observed in 90% of patients, with 8 cases showing no residual tumor. Only one patient had an unexpected positive peribronchial lymph node.<br /><br />After neoadjuvant therapy, most patients were able to undergo less extensive surgeries such as lobectomy with negative margins confirmed by frozen section analysis. Only two patients still required more extensive surgeries due to bronchus invasion. No grade 3-5 treatment-related adverse events or postoperative complications were observed, and all patients achieved R0 resection.<br /><br />At a median follow-up of 18.7 months, no progression, recurrence, or death were observed. The study concludes that neoadjuvant chemoimmunotherapy followed by modified surgery may be a viable treatment option for this specific group of stage IB NSCLC patients.

Asset Subtitle

Bengang Hui

Meta Tag

Speaker Bengang Hui

Topic Early-Stage NSCLC: Pushing the Boundaries

Keywords

neoadjuvant chemoimmunotherapy

modified surgery

stage IB non-small cell lung cancer

NSCLC

feasibility study

tumor size reduction

pathological down-staging

complete regression

lobectomy

R0 resection